Mosanna Therapeutics Announces A Seed Financing Round To Advance Development Of Mos118 To Treat Metabolic Obstructive Sleep Apnea
Mosanna Therapeutics Announces A Seed Financing Round To Advance Development Of Mos118 To Treat Metabolic Obstructive Sleep Apnea
07/13/22, 11:01 AM
Location
baselIndustry
consumer goods
software
internet services
Round Type
seed
Mosanna Therapeutics AG, a Swiss Biotech company today announced that it has secured seed financing led by Forty51 Ventures to pursue the development of AVE0118 which will be referred to as MOS118 going forward, a small molecule developed by Sanofi S.A. (Paris, France).
Company Info
Company
Mosanna Therapeutics
Location
basel, basel city, switzerland
Additional Info
The company confirmed the appointment of co-founder Dr. Jonathan Talbot as Chief Executive Officer, who said, "I'm excited to develop a treatment for one of the modern world's growing, global health crises. The company also announced the appointment of industry veteran Ben Machielse as Chairman of the Board.